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Abstract
Background: New interventions tools are a priority for schistosomiasis control and elimination, as the disease is still highly
prevalent. The identification of proteins associated with active infection and protective immune response may constitute
the basis for the development of a successful vaccine and could also indicate new diagnostic candidates. In this context,
post-genomic technologies have been progressing, resulting in a more rational discovery of new biomarkers of resistance
and antigens for diagnosis.
Methodology/Principal Findings: Two-dimensional electrophoresed Schistosoma mansoni adult worm protein extracts
were probed with pooled sera of infected and non-infected (naturally resistant) individuals from a S. mansoni endemic area.
A total of 47 different immunoreactive proteins were identified by mass spectrometry. Although the different pooled sera
shared most of the immunoreactive protein spots, nine protein spots reacted exclusively with the serum pool of infected
individuals, which correspond to annexin, major egg antigen, troponin T, filamin, disulphide-isomerase ER-60 precursor,
actin and reticulocalbin. One protein spot, corresponding to eukaryotic translation elongation factor, reacted exclusively
with the pooled sera of non-infected individuals living in the endemic area. Western blotting of two selected recombinant
proteins, major egg antigen and hemoglobinase, showed a similar recognition pattern of that of the native protein.
Concluding/Significance: Using a serological proteome analysis, a group of antigens related to the different infection status
of the endemic area residents was identified and may be related to susceptibility or resistance to infection.
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Introduction
Schistosomiasis is one of the most important parasitic diseases,
being prevalent in 76 countries [1]. Despite many control efforts,
mainly after the introduction of a chemotherapeutic treatment in
1980s, the disease is still highly prevalent [2]. The control of the
main medically important species Schistosoma mansoni, Schistosoma
japonicum and Schistosoma haematobium is based on the use of prazi-
quantel, the only drug available for chemotherapy [3]. The use of
the chemotherapy has a clear effect on morbidity [4,5]. However,
repeated mass drug administration has exerted selective pressure
on parasite population and resistance to praziquantel is being
described by different investigators [6].
The development of long-term protection based on vaccination
would be of significant benefit for disease control [7]. Despite a
large body of research in this area and one ongoing clinical trial
[8], there is no effective vaccine against schistosomiasis. Together
with the fact that mass drug administration has been applied
widely and the increasing drug pressure on the parasite popu-
lation, it becomes more evident the need to find alternative
methods of schistosomiasis control/elimination. In this context
development of an effective vaccine is a plausible alternative.
The lack of understanding of the protective immunological
mechanisms, and the difficulty in identifying antigens which
stimulate such a response, remain the major barriers towards
the development of anti-schistosome vaccines [9]. Many single
antigens with potential use as a vaccine have been proposed, but
most have showed disappointing results even with different
immunization schemes and experimental models [10,11]. Never-
theless, distinct observations in animals and humans indicate that
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it is feasible to achieve protection against infection. Significant
levels of protection were obtained in experiments with irradiated
cercariae [12] and with some recombinant antigens [13–16].
Furthermore, several reports from our group and others have
suggested that resistance to infection is acquired naturally or drug
induced [17–21]. In our studies specifically, we have shown that
resistance may develop naturally in endemic areas, describing a
group of individuals, that live in areas where transmission is active
but do not get infected, called Endemic Normals [22]. These
individuals were defined using specific criteria such as being S.
mansoni egg-negative over 5 years despite continuous exposure to
contaminated water, no previous treatment with anthelmintic
drugs and having vigorous cellular and humoral immune response
to crude schistosome antigen preparations [23,24]. The immune
response of individuals with natural resistance to schistosomiasis
differs significantly from that of post-treatment resistant and
infected individuals [17].
The immunological mechanisms that prevent the infection in
drug-induced and naturally resistant individuals living in endemic
areas for schistosomiasis may constitute the basis for the
development of a successful vaccine [7,25,26]. Therefore, we
believe that using the most recent technology to identify antigens
reactive to antibodies from resistant individuals, both natural and
drug induced, we will be able to screen at a much faster pace for
putative protective antigens.
Schistosomiasis control will benefit from a vaccine, but a new
generation of diagnostic tools is as much a part of any control and
eradication strategy. Available tools, especially fecal exams,
encounter limitations in low parasitic load and low infection rates
settings and in the follow-up to treatment [27,28]. The next
generation of assays needs to be simple, inexpensive, fast, sensitive,
specific and capable of distinguishing active from prior infection
[28,29].
The empirical science used in the last decades is strikingly
changing with the use of high throughput global approaches to a
less biased, and more encompassing development for the
proposition of new biomarkers to the discovery of vaccine
candidates, drug and diagnostic targets [24,25,30]. Significant
progress has been made in S. mansoni and S. japonicum proteomic
studies, mainly with the description of proteins differentially
expressed in the different life cycle stages of the parasite [31–33],
between male and female worms [34] and irradiated and normal
cercariae [35]. Furthermore, proteomic studies have concentrated
mainly on the studies of proteins exposed on the parasite surface
and readily accessible to the host, i.e. identification of tegumental
proteins [36–42] or secreted/excreted proteins [38,43–49].
A combination of proteomic and serological analyses has been
used as a promising experimental approach for screening new
biomarkers candidates to different diseases, identifying proteins
useful for diagnosis, therapy and vaccine design [50–54]. A limited
number of studies have performed serological-proteomic analysis
using schistosome proteins. Serum of experimentally infected
animals was used to screen antigens of S. japonicum in two-
dimensional electrophoresis (2-DE) in an attempt to identify
suitable antigens for diagnostic purposes, identifying four proteins
out of 30 immunoreactive protein spots [30]. Comparative
proteomic and immunological analysis of S. haematobium, S. bovis
and Echinostoma caproni revealed some common cross-species
antigens and species-specific targets [55]. Additional studies using
S. mansoni immunoprecipitated proteins from protective and non-
protective rat serum analyzed by 2-DE showed four spots
specifically reactive with the protective rat serum [56]. High and
low worm burden serum from infected Rhesus macaques were
used to probe S. mansoni gut secretions and tegument surface
proteins in 2-DE. The study identified gut digestive enzymes,
tegument surface hydrolases and antioxidant enzymes as IgG
targets of the IgG high titer serum of low burden animals [57].
The use of infected human serum was conducted only for S.
haematobium, where a total of 71 immunoreactive protein spots
were identified as 26 different proteins [58–60].
Although important observations have been made in relation to
schistosome antigen identification, a human schistosomiasis
mansoni coherent screening for new antigens is still necessary.
In the present study we used, for the first time, serum antibodies of
infected and naturally resistant individuals from a S. mansoni
endemic area to compare the recognition profiles of adult worm
antigens by these serum antibodies using two-dimensional Western
blotting. We identified a total of 47 S. mansoni antigenic proteins.
We also observed that some of the antigens were differentially
recognized by antibodies of infected and naturally resistant
individuals. This panel of antigens may constitute an informative




This research was approved by the Ethics Committee for
Human Research of CPqRR – FIOCRUZ (CAAE: 1.0.245.000-
08). Written informed consent was obtained from all participants
at the time of the stool collection.
All procedures involving animals were conducted in compliance
with the Manual for the Use of Animals/FIOCRUZ and
approved by the Ethics Committee on the Use of Experimental
Animal (CEUA – FIOCRUZ) license number LW-17/09.
Biological material
BALB/c mice were infected by the subcutaneous route with 100
S. mansoni cercariae of the LE strain. After 45 days, adult worms
were recovered by perfusion of the portal mesenteric system, as
Author Summary
Despite intensive efforts towards disease control, schisto-
somiasis is still highly prevalent in most endemic countries.
Although effective treatment is available and widely used,
it does not prevent reinfection, as it could be achieved
with the use of a vaccine. Efforts to control and eradicate
schistosomiasis rely on praziquantel, the only drug
available for treatment. Therefore, the identification of
antigens that can induce protective immunity is highly
desirable, as well as the need for more sensitive assays,
useful to detect low intensity infections and treatment
follow-up. The occurrence of natural resistance in schisto-
some endemic areas suggests that there is protective
immunity. However, the mechanisms involved in protec-
tion, or the proteins that induce this protective immunity,
are not yet known. These proteins, once identified, may
constitute the basis for a successful vaccine. In this study,
we compared the profile of reactive proteins to the serum
antibodies of infected and non-infected individuals resid-
ing in a schistosomiasis endemic area using two-dimen-
sional western blotting. The association of proteomic and
serological screening methodologies enabled the identifi-
cation of immunogenic proteins of the parasite, which
could be an informative source for the development of
vaccines and new diagnostic assays. In this manuscript we
describe the discovery of potential candidate proteins for
subsequent testing as protective or diagnostic antigens.
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described by Pellegrino and Siqueira [61]. The adult worms were
washed three times in RPMI medium (SIGMA), snap frozen in
liquid nitrogen and stored at 270uC until use.
Preparation of protein extracts
S. mansoni adult worm total protein extract (AW-TOT) was
obtained from direct lysis of the parasites in lysis buffer [8 M Urea,
2 M Thiourea, 4% 3-3-Cholamidopropyl-dimethylammonio-
propane-sulfonate (CHAPS), 50 mM dithiothreitol (DTT),
20 mM Tris and Complete Mini Protease Inhibitor Cocktail
Tablets (Roche)]. After homogenization under continuous agita-
tion for 2 hours at room temperature, followed by 10 repeated
passages through a 30-gauge hypodermic needle, the homogenate
was centrifuged at 20,0006g for 30 min at 25uC and the
supernatant was collected and stored at 270uC until use.
S. mansoni adult worm tegument protein extract (AW-TEG) was
obtained by freeze/thaw/vortex method in Tris Buffered Saline
(TBS) supplemented with Complete Mini Protease Inhibitor
Cocktail Tablets, according to Roberts and co-workers [62] with
some modifications. Briefly, after thawing on ice, the outer
tegumental membrane complex was removed by ten 1 second
vortex pulses at maximum speed. All the supernatant content,
obtained after decanting the stripped worms, was passed through a
30-gauge hypodermic needle 10 times and then concentrated
using a 3 kDa cutoff centrifuge filter (Millipore). Next, acetone
precipitation was performed and the pellet was solubilized in SBI
buffer [7 M Urea, 2 M Thiourea, 15 mM 1,2-diheptanoyl-sn-
glycero-3-phosphatidylcholine (DHPC), 0.5% Triton X-100,
20 mM DTT and Complete Mini Protease Inhibitor Cocktail
Tablets], as described by Babu and co-workers [63], and stored at
270uC until use.
Protein concentration of both protein extracts was measured by
the Bradford method [64] and the quality of the extracts was
verified by SDS-PAGE 12% [65].
Human serum samples collection
The human serum samples were obtained from a rural
population of the Virgem das Grac¸as village (VDG). This is a
hyperendemic area for schistosomiasis located in the Jequitinhonha
Valley in northern Minas Gerais State, Brazil. In VDG there is no
treated water or basic sanitation and water contact was determined
by direct observation and translated to Total Body Minutes (TBM).
Stool samples were processed by the Kato-Katz method to detect
eggs of S. mansoni and other intestinal helminthes. Two slides from
each stool sample collected in three consecutive days were used for
quantification of number of eggs/gram of stool [66].
In the present study, the serum samples were chosen according
to the following criteria: individuals not infected by other
helminthes (Ascaris lumbricoides, Trichuris trichiura and Ancylostoma),
between 20–50 years of age, man or non-pregnant women.
Individuals positive for S. mansoni eggs at the start of the study in
2001 were called Infected Individuals (INF), and those who were
egg negative in the three years of the study (2001, 2002 and 2006)
were identified as Non-Infected Individuals from Endemic Area
(NE). All the serum samples used in this study were obtained at the
initiation of the study in January 2001, before mass chemotherapy
with praziquantel was administered. Serum samples of 13 INF,
who had 8 to 304 eggs/gram of stool, and 9 NE were used
(Table 1). Sera of Non-Infected volunteers from non-endemic sites
(NI) were also used in this study, 7 from USA or 2 from UK sites.
Two-dimensional electrophoresis (2-DE)
For each two-dimensional-polyacrylamide-gel-electrophoresis
(2D-PAGE), 100 mg of proteins from AW-TOT or AW-TEG
extracts were used. The AW-TOT proteins were solubilized in
IEF rehydration buffer [8 M Urea, 2 M Thiourea, 4% CHAPS,
0.0025% bromophenol blue, 65 mM DTT and 1% BioLyte 3–10
buffer 1006 (Bio-Rad)] and the AW-TEG proteins in SBI buffer
supplemented with 0.0025% bromophenol blue and 0.4% BioLyte
3–10 buffer 1006 (Bio-Rad) [63], both to 125 ml final volume.
After homogenization under continuous agitation for 1 hour at
room temperature, the samples were centrifuged at 16,0006g for
30 min. The supernatants were loaded onto 7 cm IPG strip 3–10,
3–10NL or 5–8 pH ranges (Bio-Rad) by in-gel sample rehydration.
Isoelectric focusing was carried out in a Protean IEF Cell (Bio-
Rad) at 20uC and 50 mA/strip. Passive rehydration was performed
for 4 hours, followed by active rehydration at 50 V for 12 hours,
and focalization at 500 V for 30 min, followed by 1,000 V for
30 min, 4,000 V for 1 hour and 4,000 V up to 16,000 V/h. The
IPG strips were equilibrated in reducing buffer (6 M Urea, 30%
glycerol, 2% SDS, 50 mM Tris-HCl pH 8.8, 0.001% bromophe-
nol blue and 130 mM DTT) for 10 min, and in alkylating buffer
containing 135 mM iodoacetamide for a further 10 min. The IPG
strips and molecular weight standard were placed on top of 12%
SDS-PAGE gels and sealed with 0.5% agarose. The second
dimension electrophoretic protein separation was carried out using
Table 1. Selected volunteers from the endemic area of
schistosomiasis, Virgem das Grac¸as, Brazil.
Volunteers ID Localization Gender Age EPG TBM
Infected (n =13)
31 cVDG F 25 88 229
58 cVDG F 33 8 157
128 cVDG M 28 200 91
129 cVDG F 33 304 126
189 cVDG F 31 48 117
214 cVDG F 35 80 187
238 cVDG F 34 20 284
329 Suss F 38 8 126
356 Card1 M 37 48 184
371 Card1 F 26 160 163
403 Card2 M 36 152 118
493 Card3 F 49 43 143
514 Card3 F 43 212 89
Non-Infected (n = 09)
62 cVDG/Card2 M 33 0 155
83 cVDG M 27 0 107
115 cVDG M 46 0 93
233 cVDG F 40 0 156
294 Suss F 24 0 -
312 Suss M 37 0 88
366 Card1 M 37 0 -
445 Card2 F 49 0 124
609 cVDG F 28 0 53
Volunteers ID: identity number of the selected volunteers. Localization: sites of
volunteers in the village (cVDG: central village of Virgem das Grac¸as; Suss:
Suc¸uarana; Card1/2/3: Cardoso 1, 2 or 3). Gender: M-Male and F-Female. Age:
age of volunteers at the serum collection in 2001. EPG: Eggs Per Gram of faeces,
from 3 samples, 2 slides each, by Kato-Katz method. TBM: Total Body Minutes,
time in minutes of body exposure to water. (-): missing data.
doi:10.1371/journal.pntd.0002745.t001
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a Mini-Protean III (Bio-Rad) under 60 V constant voltage for
10 min, and then under 100 V until the dye front reached the
bottom of the gel.
For each 2-DE experiment, at least two 2D-PAGEs were
performed in parallel, one to be used in a Western blotting
experiment and another corresponding 2D-PAGE to be stained by
Colloidal Coomassie Blue G-250 for spot excision and protein
identification.
Two-dimensional western blotting (2D-WB)
The 2D-PAGEs were immediately transferred to a PVDF-based
membrane (Immuno-blot 0.2 mm, Bio-Rad) using a Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad) at 100 V (2–3 mA cm2)
for 120 min with transfer buffer (25 mM Tris-Base, 192 mM
glycine, 20% methanol). The membranes were washed in water
and air-dried. Before proceeding with Western blotting, the
membranes were re-activated in 100% methanol and blocked for
16 hours in TBS (20 mM Tris-HCl, 500 mM NaCl, pH 7.5)
containing 0.05% Tween-20 and 3% BSA (TBS-T/3% BSA) at
room temperature. Each membrane was incubated separately for
2 hours with each pool of INF, NE or NI (from USA volunteers)
sera diluted 1:500 in TBS-T/1% BSA. After 2630 min washes in
TBS-T/1% BSA, the membranes were incubated with goat anti-
human Ig’s polyvalent antibody, HRPO conjugated (Caltag
Laboratories), diluted 1:100,000 in TBS-T/1% BSA. After
2630 min washes in TBS-T and 1615 min wash in TBS, the
immunoreactive proteins were developed using ECL Plus Western
Blotting Detection System (GE Healthcare) and the membranes
were exposed for 16 hours to X-Ray film. All the 2D-WB
experiments were performed in triplicate.
In-gel digestion
The X-Ray films and its corresponding Colloidal Coomassie
Blue stained 2D-PAGE were overlapped. The antigenic protein
spots were manually and individually excised from the corre-
sponding 2D-PAGE for mass spectrometry identification. First,
spots were washed in Milli-Q water, and then destained 2615 min
in 50% acetronitrile (ACN)/25 mM ammonium bicarbonate (AB)
pH 8.0 until clear of blue stain. The gel fragments were dried in
100% ACN for 5 min, followed by rehydration in 100 mM AB for
5 min and addition of same volume of 100% ACN. The solution
was removed and 100% ACN was added again. After removing
the ACN, the spots were completely dried in a Speed Vac
Concentrator Plus (Eppendorf) for 20 min. The final dried spots
were re-swollen in 10 ml of 20 mg/ml Sequencing Grade Modified
Trypsin (Promega) in 25 mM AB for 10 min and then, additional
10 ml of 25 mM AB were added. Protein digestion was conducted
at 37uC for 16 hours. After the incubation, the supernatant was
transferred to a clean tube and 30 ml of 5% formic acid (FA)/60%
ACN were added to gel spots for the extraction of the tryptic
peptides. This procedure was performed 2630 min under
constant agitation. The supernatant was pooled to the respective
tube containing the initial peptide solution. This solution was dried
in a Speed Vac and the peptides were resuspended in 8 ml of 0.1%
FA. The peptides were desalted in reverse phase micro-columns
Zip Tip C18 (Millipore), according to manufacture instructions.
Peptides were dried again and resuspended in 1 ml of 50% ACN/
0.1% trifluoracetic acid (TFA) solution.
Protein identification by mass spectrometry
MALDI-ToF-ToF analysis was performed on the 4700
Proteomics Analyzer (Applied Biosystems). Briefly, 0.5 ml of the
micro-column eluate was mixed with 0.2 ml of alpha-cyano-4-
hydroxycinnamic acid matrix (20 mg/ml in 30% ACN/0.3%
TFA). Samples were spotted onto the ABI 192-targed MALDI
plate by co-crystallization and mass spectrometry data were
acquired in positive and reflectron mode, mass range 900–
4,000 Da, using a neodymium-doped yttrium aluminum garnet
(Nd: YAG) laser with a 200-Hz repetition rate. Typically, the
analyses were conducted using 2,000 shots of MS and 4,000 shots
of MS/MS to the 10 most abundant ions. External calibration was
performed using a mixture of four peptides: des-Arg1-bradykinin
(m/z= 904.47), angiotensin I (m/z= 1296.69), Glu1-fibrinopep-
tide B (m/z= 1570.68) and adrenocorticotropic hormone (18–39)
(m/z= 2465.20) (mass standards kit for the 4700 Proteomics
Analyzer). The list of peptide and fragment mass values generated
by the mass spectrometer for each spot were submitted to a MS/
MS ion search using MASCOT (Matrix Science, Boston, MA) to
search in the NCBInr database. The parameters used were:
allowance of two tryptic miss cleavages, peptide error tolerance of
60.6 Da, MS/MS error tolerance of 60.2 Da, peptide charge +1
and variable modifications of methionine (oxidation), cysteine
(carbamidomethylation and propionamidation). To avoid random
matches, only ions with individual score above of the indicated by
the MASCOT to identity or extensive homology (p,0.05) were
considered for protein identification. To those protein matches
obtained from NCBInr search that did not retrieve a Smp
number, a blastp search was conducted using the SchistoDB
database Version 2.0 (www.schistodb.net) [67].
Clustering analysis of immunoreactive proteins
Hierarchical clustering was performed with the identified
immunoreactive proteins according to similarities in recognition
profile with each pool of serum used in this study, in three two-
dimensional Western blotting assays. Recognition profile similarity
was measured by the Euclidean distance, with complete-linkage
among samples, using the Hierarchical Clustering (HC) algorithm
available at the GenePattern Platform [68].
Cloning, in vitro expression and western blotting analysis
of the recombinant S. mansoni hemoglobinase and
major egg antigen
The S. mansoni hemoglobinase precursor (Smp_075800) and
major egg antigen (Smp_049300.3) were expressed using a wheat
germ cell-free expression system (TNT SP6 High-Yield Wheat
Germ Protein Expression System, Promega) by coupled in vitro
transcription-translation. The coding region of the corresponding
genes were obtained by PCR amplification using a previously
constructed S. mansoni adult worm cDNA library as template.
Primers were designed using the Flexi Vector Primer Designer
Tool (Promega), adding an extra C-terminal histidine tag. The
primers used to amplify the coding region of major egg antigen and
hemoglobinase genes were as follow: forward (59-GGCTGCGA-
TCGCCATGTCTGGTGGGAAACAACATA-39) and reverse
(59-TGATGTTTAAACGTGGTGGTGGTGGTGGTGAGTA-




reactions were composed of 25 ml JumpStart REDTaq ReadyMix
Reaction Mix (Sigma-Aldrich), 2.5 ml of each gene specific
forward and reverse primer (10 mM), 2 ml of S. mansoni adult
worm cDNA library in 50 ml final volume. The purified PCR
products were inserted into pF3A WG (BYDV) Flexi Vector
(Promega) using the Flexi Vector System (Promega) and the
plasmids were transformed into electrocompetent DH5a Esche-
richia coli cells by electroporation. Colonies were selected and
Schistosoma mansoni Proteome Serological Screening
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grown in LB-Amp broth. Plasmids were purified using QIAprep
Spin Miniprep Kit (Qiagen) and verified by DNA sequencing
using the SP6 and T7 terminator primers (Source Bioscience,
Nottingham, UK). Protein synthesis was initiated by adding the
DNA plasmids as template according to the instructions described
in the TNT SP6 High-Yield Wheat Germ Protein Expression
System protocol. Protein expression was analyzed by the
incorporation of labeled lysine residues (FluoroTect GreenLys,
Promega) loading 5 ml of the reaction in 4–20% Mini-PROTEAN
TGX Precast Gel (Bio-Rad) and detecting with a laser-based
fluorescent gel scanner (Fujifilm LAS-4000 Imaging System).
For Western blotting analyzes, 3 ml of the protein synthesis
reaction were blotted onto 0.45 mm nitrocellulose membranes
after electrophoresis. The membranes were blocked for 16 hours
in TBS-T/3% nonfat dry milk and then incubated separately for
2 hours with each pool of INF, NE or NI (from UK volunteers)
sera diluted 1:500 in a pre-adsorbed solution. These serum pools
were pre-adsorbed for 16 hours in TBS-T/3% nonfat dry milk
and 5% wheat germ protein extract. After 2630 min washes in
TBS-T/1% nonfat dry milk, membranes were incubated with
rabbit anti-human IgG antibody (Sigma) diluted 1:10,000 in TBS-
T/1% nonfat dry milk for 1 hour and with anti-rabbit IgG HRP
conjugated (ECL Plus Western Blotting Reagent Pack, GE
Healthcare) in the same conditions, with 2630 min washes
between antibodies incubations. The membranes were revealed
using ECL Plus-Western Blotting Detection System (GE Health-
care) and the proteins were visualized by chemiluminescence
detection using a Fujifilm LAS-4000 Imaging System.
Results
Schistosoma mansoni adult worm antigens recognized by
antibodies in pooled sera of infected individuals
S. mansoni adult worm total and tegumental protein extracts
were used initially in 2D-WB in order to evaluate the antigenicity
of proteins using total immunoglobulins in pooled sera of S. mansoni
infected individuals.
Firstly, Colloidal Coomassie Blue stained 2D-PAGEs were
conducted using different IPG strip pH ranges (3–10, 3–10NL and
5–8) in order to visualize the separation pattern of the AW-TOT
protein extract. All the different IPG strip pH ranges used showed
good resolution of the spots and minimal streaking. Protein spots
were reproducibly resolved in a broad pH range and molecular
weight (Figure 1A).
Corresponding 2D-WB using each of the IPG strip pH ranges
were performed to determine which pH range would better
separate the immunoreactive protein spots when using pool of INF
serum against AW-TOT protein extract. The use of IPG strip 3–
10, 3–10NL and 5–8 pH ranges showed that distinct antigenic
spots were evidenced when resolved by different IPG strip pH
ranges (Figure 1B). Although most of the antigenic proteins were
common among all the IPG strip pH range used, some proteins
were exclusively identified in specific IPG strip pH range,
contributing to increase the total number of identified immuno-
reactive proteins (Table 2).
AW-TEG protein extract was also used in an attempt to enrich
the analysis with immunologically exposed parasite proteins. The
AW-TEG protein extract was separated in pH 3–10 IPG strip and
it was observed a distinct 2D-PAGE and 2D-WB pattern to the
AW-TOT protein extract, although there are some common
immunoreactive protein spots in both extracts (Figure 1).
When the 2D-WB X-Ray films and the corresponding Colloidal
Coomassie Blue stained 2D-PAGEs were overlapped it was
observed that there was no direct correlation between the amount
of protein in the AW-TOT and AW-TEG protein extracts and its
antigenicity level. Although the most of immunoreactive spots
recognized by the INF serum were visible in its corresponding 2D-
PAGE, there were some strongly stained protein spots that showed
weak or no immunoreactivity (dashed circles in Figures 1A and
1B). Conversely, there were some barely visible protein spots in the
2D-PAGE that were highly immunoreactive (circles in Figures 1A
and 1B). Most of the immunoreactive protein spots show a pI
above 6.5 and molecular weight above 25 kDa.
Immunoreactive spots visualized in each of the pH ranges were
excised from the corresponding Colloidal Coomassie stained 2D-
PAGE for proteins identification by mass spectrometry (MS/MS).
A total of 37 immunoreactive spots were excised from the 2D-
PAGE using AW-TOT protein extract and pH 3–10 IPG strip.
Additional 37 and 39 spots were excised from the 2D-PAGE using
the pH 3–10NL IPG strip and the pH 5–8 IPG strip, respectively.
From the 2D-PAGE using AW-TEG protein extract, 36 immu-
noreactive spots were excised. Some of the protein spots could not
be identified by MS/MS. Using AW-TOT protein extract and
pH 3–10 and pH 5–8 IPG strips, 7 and 14 immunoreactive spots
were not MS/MS identified, respectively. Two immunoreactive
spots from the 2D-PAGE using AW-TEG protein extract were
also not identified (gray circles in Figure 1C).
A total of 47 different S. mansoni immunoreactive proteins were
identified. Using AW-TOT protein extract 22, 29 and 18 proteins
were identified from 2D-PAGE of pH 3–10, pH 3–10NL and
pH 5–8, respectively. AW-TEG protein extract yielded 25
proteins identified from 2D-PAGE of pH 3–10. Most proteins
were identified in more than one pH range, but others were
exclusive. Additionally, 9 immunoreactive proteins were identified
only in AW-TEG protein extract (Figure 2). All proteins identified
by mass spectrometry in at least one 2D-WB experiment were
included (Table 2). In some cases, as the result of post-translational
modifications, splice variants or paralogue genes, for example, the
same protein description was identified for different immunoreac-
tive spots, but a representative gene ID was used.
Comparative serology of Schistosoma mansoni adult
worm proteins
In order to identify antigens differentially recognized by
antibodies from pooled sera of S. mansoni infected (INF) and
non-infected (NE) individuals from the endemic area, 2D-WB
experiments were performed using both serum pools. A serum
pool of non-infected individuals from a non-endemic area (NI) was
also used. AW-TOT and AW-TEG protein extracts were focused
using pH 3–10 IPG strips. Four 2D-PAGEs were electrophoresed
simultaneously. Three of them were used in the 2D-WB with the
three serum pools separately (INF, NE, NI). The fourth gel was
stained with Colloidal Coomassie for spot excision and MS/MS
identification.
Quantitative variations on the reaction intensity of the
immunoreactive spots were observed among the 2D-WB using
the same dilution of the three pooled sera. However, a similar
overall pattern of reactive spots was observed, but with higher
signal intensity when using the INF serum pool when compared to
the NE, which in turn showed higher signal intensity than NI
serum pool (Figure 3).
Qualitative variations of the immunoreactive spots were also
visualized among the 2D-WB. Using AW-TOT and AW-TEG
protein extracts it was observed that 9 spots were detectable
exclusively with the INF serum pool and a single spot exclusively
with the NE serum pool (Table 3). From those that reacted only
with the INF serum pool, some strong immunoreactive spots of
40 kDa with approximately pI 7.0 were observed, as indicated by
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a circle in Figure 3. Interestingly, the corresponding spots in the
2D-PAGE were weakly stained (Figure 1A). The spots excised
from this region in the 2D-PAGE were identified as major egg
antigen, annexin and troponin T proteins. Two spots correspond-
ing to major egg antigen were identified in all the triplicate assays
of both AW protein extracts (spots 14 and 15 in Figure 4 and
Table 3). One extra spot of the major egg antigen was identified in
all triplicate assays of AW-TEG protein extract (spot 42 in Figure 4
and Table 3). The presence of major egg antigen was confirmed in
all of the IPG strip pH ranges using the INF serum pool (Table 2).
Annexin was identified in all triplicate assays of the AW-TEG
protein extract, but major egg antigen was co-extracted in the
same spot as they co-migrate (spot 41 in Figure 4 and Table 3).
Two spots corresponding to troponin T were identified in the AW-
TOT protein extract (spots 31 and 32 in Figure 4 and Table 3).
However, they were not present in all 2D-WB triplicate
experiments, two experiments showed the spot 32 and one, the
spot 31 (Figure 4 and Table 3). Other two spots, also
immunoreactive only with the INF serum pool, were localized
above 60 kDa, within a pH range 6.0 and 7.0 in the triplicate of
AW-TEG protein extract, as pointed by arrows in the Figure 3.
The corresponding proteins were identified as disulphide isomer-
ase ER-60 precursor and filamin (spots 44 and 45, respectively, in
Figure 4 and Table 3). From spot 21 indicated by the arrowhead
in the Figure 3, two proteins were co-excised: actin and
reticulocalbin (Figure 4 and Table 3), with low pI and at
Figure 1. 2D-PAGE and 2D-WB of Schistosoma mansoni adult worm protein extracts using different IPG strip pH ranges. A) 2D-PAGE of
adult worm total (AW-TOT) and tegumental (AW-TEG) protein extracts using 7 cm, pH 3–10, 3–10NL and 5–8 IPG strips and SDS-PAGE 12%, stained
by Colloidal Coomassie Blue G-250. B) Corresponding 2D-WB using pool of S. mansoni infected individuals serum and anti-human Ig’s polyvalent
antibody HRPO conjugated. The dashed circle indicates a region of strongly stained protein spots in 2D-PAGE that are weakly or not immunoreactive
in 2D-WB and the circle indicates a region of protein spots barely visible in 2D-PAGE and highly immunoreactive. C) Schematic representation of
immunoreactive spots excised from the corresponding 2D-PAGE to MS/MS identification. Gray circles represent immunogenic spots not identified
and black circles represent immunogenic spots identified by MS/MS. All the identified proteins are listed in Table 2. The figure shows one
representative experiment of three replicates.
doi:10.1371/journal.pntd.0002745.g001
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Table 2. Immunoreactive proteins to the pooled sera of individuals from the schistosomiasis endemic area.
PROTEIN DESCRIPTION GENE ID IPG strip pH range
3–10 3–10 NL 5–8 3–10
AW-TOT AW-TEG
14.3.3 epsilon isoform Smp_034840.3 x x x x
14.3.3 zeta isoform Smp_009760 x x x
Actin-11 Smp_046600 x x x x
Aldehyde dehydrogenase Smp_050390 x x x x
Antigen Sm 21.7 Smp_086480 x x
Annexin2 Smp_162170.2 x
Arginase Smp_059980 x
ATP synthase alpha subunit mitochondrial Smp_002880.2 x x
ATP synthase beta subunit Smp_038100 x x
ATP: guanidino kinase (Smc 74) Smp_194770 x
Cathepsin B1 isotype 1 Smp_103610 x
Cathepsin B1 isotype 2 Smp_067060 x
Cofilin actophorin Smp_120700.1 x
Dynein light chain Smp_095520 x
Enolase (Phosphopyruvate hydratase) Smp_024110 x x x x
Eukaryotic translation elongation factor Smp_143140 x
Fatty acid-binding protein (Sm14) Smp_095360.3 x
Filamin Smp_000100 x
Four and A half lim domains4 Smp_048560 x x
Fructose 1,6-biphosphate aldolase Smp_042160.2 x x x
Gelsolin Smp_008660.2 x
Glutathione S-transferase 28 kDa (GST-28) Smp_054160 x x x x
Glutathione S-transferase 26 kDa (GST-26) Smp_102070 x x
Glyceraldehyde-3-phosphate dehydrogenase Smp_056970.1 x x x x
Gynecophoral canal protein Smp_177050 x
Heat shock protein 70 (HSP70) Smp_106930 x x x
Hemoglobinase precursor (Antigen Sm32)* Smp_075800 x x x
Hydroxyacylglutathione hydrolase (Glx II) Smp_091010 x
Major egg antigen* Smp_049300.3 x x x x
Malate dehydrogenase3 Smp_035270.2 x x
Malate dehydrogenase3 Smp_047370 x
Myosin regulatory light chain Smp_132670 x x x
Ng,ng- dimethylarginine dimethylaminohydrolase Smp_052560 x x
Phosphoglycerate kinase5 gi|1172460 x x x
Phosphoglycerate mutase Smp_096760 x x x x
Protein disulfide-isomerase ER-60 precursor Smp_079770 x
Reticulocalbin1 Smp_147680 x x x
Schistosoma mansoni, expressed protein Smp_171780 x x
Short-chain dehydrogenase4 Smp_081430 x
Superoxide dismutase [Cu-Zn] Smp_176200.2 x
Superoxide dismutase [Mn] Smp_056440 x
Transketolase Smp_059790.2 x
Trimeric G-protein alpha o subunit Smp_016630.2 x
Triose phosphate isomerase Smp_003990 x x
Troponin I (S. japonicum)6 gil226481381 x
Troponin T Smp_179810 x
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approximately 45 kDa. This spot was immunoreactive in the
triplicate of AW-TEG protein extract and in one of the triplicate
2D-WB experiment of the AW-TOT protein extract when probed
with INF serum pool (Figure 3). The transketolase (spot 24 in
Figure 4 and Table 3) was identified as an immunoreactive spot
exclusively when probed with INF serum pool in one 2D-WB
experiment of the AW-TOT triplicate. However, in two 2D-WB
experiments of the AW-TEG triplicate this protein was immuno-
reactive to both INF and NE serum pools.
Only one immunogenic spot reacted exclusively with NE serum
pool in two 2D-WB experiments of the AW-TEG triplicate. This
spot of approximately 33 kDa and pI 8.0, as indicated by a dotted
circle in Figure 3, corresponds to eukaryotic translation elongation
factor (spot 40 in Figure 4 and Table 3). Although highly
immunoreactive, this protein showed a low expression levels in
AW-TEG protein extract (Figures 3 and 4).
All the immunoreactive proteins were clustered by Euclidean
distance with complete-linkage method according to reactivity
pattern against INF, NE and NI serum pools in triplicate assays
with AW-TOT (Figure 5A) and AW-TEG (Figure 5B). Using the
heat map representation, the proteins which reacted exclusively
with antibodies from the INF serum pool were clustered, and it
was highlighted that the protein recognition pattern by NE and NI
serum pools is closer than the NE and INF serum pools (Figures 5A
and 5B).
In vitro expression and western blotting analysis of
recombinant Schistosoma mansoni major egg antigen
and hemoglobinase
Two proteins identified in the 2D-WB experiments were
selected for further validation of the immunoreactive pattern to
the serum pools as recombinant protein expressed in a cell free in
vitro system. The major egg antigen (MjE) was selected since it was
identified in several spots immunoreactive only to the INF serum
pool in the 2D-WB experiments (spots 14, 15, 41 and 42 in
Table 3) using AW-TOT and AW-TEG protein extracts. The
hemoglobinase precursor (Hem) was also selected since it was
identified using all serum pools in the 2D-WB (spot 11 in Table 3).
The coding region of the genes encoding these proteins was
successfully amplified by PCR using S. mansoni adult worm cDNA
library as template. The amplified fragments were inserted into
pF3A WG (BYDV) Flexi Vector and the sequences confirmed by
DNA sequencing. The in vitro coupled transcription-translation
using the wheat germ system showed to be a suitable approach for
expression of these schistosome proteins. The expressed proteins
were visualized in the SDS-PAGE with the expected theoretical
molecular mass, 40.3 kDa for MjE and 47.7 kDa for Hem,
including the 66His-tag (Figure 6A, lanes 1 and 2, respectively). In
the negative control reaction, without DNA template, two protein
bands of approximately 17 kDa were observed, as well as in the
reactions using the plasmids containing the coding region of
MjE and Hem. These bands correspond to newly synthesized
biotinylated translation products of the TNT SP6 High-Yield
Master Mix, which incorporate the labeled amino acid FluoroTect
GreenLys and are seen as background (Figure 6A, lane 3). In the
reaction using no DNA plasmid template and no FluoroTect
GreenLys no fluorescent translation products were observed
(Figure 6A, lane 4).
Western blotting analysis of recombinant proteins expressed by
in vitro wheat germ expression system was performed using serum
pool of S. mansoni infected (INF) and non-infected (NE) individuals
from endemic area and also of non-infected volunteers (NI). The
recombinant proteins maintained the recognition pattern of INF
and NE serum pools used in the 2D-WB experiments, confirming
their correct identification and the maintenance of the antigenic
epitopes in the in vitro expressed proteins. MjE remained strongly
reactive when tested against the INF serum pool, and was non- or
weakly reactive with NE serum pool. The Hem recombinant
protein reacted with both INF and NE serum pools, however, with
greater reaction intensity against the INF serum pool. Neither MjE
nor Hem was recognized by antibodies present in NI serum pool.
Interestingly, the NI serum pool from UK volunteers reacted with
a higher molecular weight protein from wheat germ extract, even
in the negative reaction control using no DNA plasmid template.
This reactive band was not observed using serum pools of
individuals from schistosomiasis endemic area (Figure 6B).
Discussion
S. mansoni adult worms can survive for decades in the hepatic
portal system of the vertebrate host in spite of the parasites being
constantly exposed to the host immune system and must,
therefore, display effective strategies to evade the host immune
response [69]. On the other hand, it has been well demonstrated
that the development of protective immunity against schistosomes
depends on both humoral and cell-mediated immunity [70]. In
this study, we aimed to identify parasite antigens applying an
approach that would enable the screening of a large number
of antibody targets using serum of individuals residing in a
Table 2. Cont.
PROTEIN DESCRIPTION GENE ID IPG strip pH range
3–10 3–10 NL 5–8 3–10
AW-TOT AW-TEG
Tubulin alpha chain Smp_016780 x
Total number of identified proteins: 47 22 29 18 25
All Smp IDs can be found in schistodb.net. AW-TOT: adult worm total protein extract, AW-TEG: adult worm tegumental protein extract.
1: actin was co-extracted from the same spot with reticulocabin, except in pH 5–8 IPG strip;
2: annexin was co-extracted from the same spot with one of major egg antigen;
3: the same protein corresponding to different spots and protein sequences;
4: short-chain dehydrogenase was co-extracted from the same spot with four and A half lim domains;
5: gene ID corresponding to Smp_018890 and Smp_187370;
6: troponin I from S. japonicum;
*: proteins selected to in vitro recombinant protein expression.
doi:10.1371/journal.pntd.0002745.t002
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schistosomiasis endemic area. This approach allowed the identi-
fication of antigens associated to the disease infection or resistance
status.
A number of Schistosoma serological-proteomic studies have
already been performed. However, this is the first which was
conducted with S. mansoni using human sera, including sera of
resistant and susceptible infection individuals living in an endemic
area, allowing a more rational screening for new tangible human
biomarker discovery. Although these studies have searched for
schistosome vaccine candidates, most of them were based on
animal models, with the caveat that they may not be directly
translatable to humans [26]. In addition, similar studies with
S. haematobium may not correlate with S. mansoni, as there is
considerable variability in immune responses to crude antigens
from both parasites [71,72].
In this study we were able to identify 47 different antigenic
proteins, a slightly larger number when compared to previous
S. mansoni serological-proteomic studies. This can be attributed to
the use of different IPG strip pH ranges and to the fact that all
experiments in this study were performed in triplicate, increasing
our chances of identifying new antigens. Although previous
serological-proteomic studies were performed using protein
extracts from other Schistosoma species and serum sources, some
proteins were commonly identified such as HSP-70, enolase,
GAPDH, triose phosphate isomerase, fructose-bisphosphate
aldolase, glutathione S-transferase 28 kDa, 14-3-3 protein
[30,59,73].
Among the immunoreactive proteins several are related to
housekeeping metabolic pathways, such as glycolysis, gluconeo-
genesis and citric acid cycle; protein synthesis and proteolysis;
transport; response to stress; detoxification process; cytoskeleton
organization. In addition, some proteins that have already been
tested as vaccine candidates, such as triose phosphate isomerase
[74], glutathione S-transferase 28 kDa [75], fatty acid-binding
protein (Sm14) [13] and superoxide dismutase [76] were also
identified in this study.
For this work we decided to detect total immunoglobulins from
sera of the different groups of individuals, since there is no clear
mechanism of immunity in human schistosomiasis that defines a
class of immunoglobulin as key for an effective immune response.
Although some studies indicate IgE as an important immuno-
globulin in schistosome post-treatment resistance, a vaccine trial
for other helminth with an antigen that induces high IgE response
showed significant adverse events [17,77]. Therefore, we per-
formed an analysis of all immunoreactive proteins regardless of
immunoglobulin isotype using polyvalent anti-human Ig. Mutapi
and co-workers [60] showed that there are qualitative and
quantitative differences in S. haematobium antigen recognition
profiles by human antibody isotypes (IgA, IgE, IgG1 and IgG4)
although the majority of the adult worm antigens were recognized
by all of these four isotypes. In earlier experiments, Delgado and
McLaren [78] showed that IgG1 and IgG3 were involved in
protective immunity against S. mansoni infection in mice. To
address this possibility, we also preliminarily assayed for reactivity
using anti-IgG1 and IgG3 in our serological screening. However
we could not observe any significant differences in the antigenic
pattern of INF, NE and NI sera recognition (data not shown).
Tegumental protein extract of S. mansoni adult worm was used to
enrich our analysis with proteins that are directly exposed to host
immune response. Although a large number of proteins were
identified in both AW-TOT and AW-TEG protein extracts, there
are still some differences between these extracts to be explored.
Using 1D SDS-PAGE and LC-MS/MS, van Balkom and co-
workers [40] identified 429 proteins, from which only 43 were
specific to the tegument. All the tegumental specific proteins
identified in our study were also identified by these investigators,
and the proteins filamin and hydroxyacylglutathione hydrolase
were exclusively identified in the tegumental protein fraction in
both studies. Although we have used detergent buffer to solubilize
integral membrane proteins for 2-DE in the AW-TEG, we were
not able to identify immunoreactive proteins with transmembrane
domains, as indicated in the SchistoDB database [67]. Despite
extensive research, the large-scale analysis of membrane proteins
by 2-DE remains a difficult task [79]. It is critical that other
methods for membrane protein extraction that allow separation by
2-DE are developed.
Serum of non-infected volunteers from non-endemic schistoso-
miasis area showed immunoreactivity to some protein spots of
AW-TOT and AW-TEG. It has been previously shown by Losada
and co-workers [80] that the sharing of molecules among
organisms is an expected finding since there are several functional
molecules that are conserved during the process of evolution.
These molecules may elicit immune responses between different
species of various genera and is responsible for antigenic cross-
reactivity. According to these findings, Escherichia coli and
Saccharomyces antigens induce cross-reactivity with S. mansoni crude
antigens, sharing T- and B-lymphocyte epitopes [81,82]. Never-
theless, in our study 12 schistosome specific protein spots were
detected only when sera of INF and NE were used.
Although most immunoreactive spots were visible in its
corresponding 2D-PAGE, some highly immunoreactive protein
spots were barely visible in the 2D-PAGE. Our analysis was
conducted using only adult worm protein extracts, and there is a
different level of protein expression during the life cycle of the
parasite [31,83]. Major egg antigen protein spots showed to be
highly immunoreactive in the 2D-WB to the INF serum pool,
although poorly expressed in AW-TOT and AW-TEG protein
extracts. When a comparative analysis of the S. mansoni proteome
among the life cycle stages was described by Curwen and co-
workers [31], the major egg antigen was among the top 40
Figure 2. Venn diagram showing the number of unique and
shared proteins identified between and among 2D-WB assays.
The number of immunoreactive proteins identified using AW-TOT
protein extract and pH 3–10 IPG strip are represented in the yellow
circle, using pH 3–10NL IPG strip in red and using pH 5–8 IPG strip in
green. Spots using AW-TEG protein extract and pH 3–10 IPG strip are
represented in the blue circle. Common spots identified between and
among the assays are represented overlapped by the circles.
doi:10.1371/journal.pntd.0002745.g002
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proteins expressed in egg protein extract (SEA). Therefore, the
high level of major egg antigen immunoreactivity with the INF
serum is probably due to the host immune response to this highly
expressed protein in the parasite eggs that is also present in other
life cycle stages.
As described by Wilson and Coulson [69] a single ‘‘magic
bullet’’ has been shown not to be an efficient target for the
development of a schistosomiasis vaccine. An antigen cocktail is
suggested as a way to acquire protection. In line with this
principle, in the current study we were able to cluster proteins with
similar immunoreactivity pattern when using serum pools of
infected or non-infected individuals. We observed that the major
egg antigen, annexin, troponin T, filamin, disulphide-isomerase
ER-60 precursor, actin and reticulocalbin proteins reacted
exclusively with serum antibodies of the infected individuals and
the eukaryotic translation elongation factor with antibodies present
in the serum of the non-infected individuals from endemic area.
The major egg antigen, or Smp40, has been described as highly
immunogenic in humans [84]. The cytokine profile obtained by
PBMC from S. mansoni infected patients stimulated with purified
Smp40 was associated with a reduction of granuloma formation
and anti-pathology vaccine [85]. This protein was also previously
suggested as a potential antigen to be used in an immunodiag-
nostic test, since it was effectively immunoprecipitated by S. mansoni
infected human and chronically infected mouse serum [86,87]. As
for the Smp40 protein expression across the parasite life cycle,
Nene and co-workers [86] showed that Smp40 could be easily
detected by Western blotting assays in adults, cercariae, schisto-
somulum and egg stages, when probed with serum raised against a
p40 fusion protein. Furthermore, van Balkom and co-workers [40]
in their S. mansoni tegumental proteomics study have identified the
Smp40 in both, tegumental and stripped worms protein fractions.
Filamin proteins are mechanical linkers for actin filaments and
are also involved in signal transduction and transcription [88,89].
Filamin was previously identified in an immunoscreening of
cercarial cDNA library using IgG fraction of rabbit antiserum
raised against immature female worms. A polyclonal antiserum
specific to recombinant S. mansoni filamin revealed a tegument
associated fluorescence in adult worms that reacted mainly with a
band of 84 kDa, instead of the 280 kDa as indicated by the RNA
sequence [90]. The filamin protein spot that was identified in this
study using S. mansoni adult worm tegument protein extract was
approximately 80 kDa, suggesting that they are the same protein.
Previous studies using IgG specific antibodies to the recombinant
filamin showed 36.6% killing of schistosomula in vitro and in a
DNA vaccine immunization filamin induced a mean of 50%
protection in mouse following challenge with adult worms by
surgical transfer [90,91].
Troponin T is one of the three protein subunits of the tro-
ponin complex that mediate Ca2+-regulation that governs the
Figure 3. 2D-WB of Schistosoma mansoni adult worm total and tegumental protein extracts using pooled sera of infected, non-
infected from endemic area and non-infected from non-endemic area individuals. Adult worm total (AW-TOT) and tegumental (AW-TEG)
protein extracts were separated by 2-DE using 7 cm pH 3–10 IPG strips and SDS-PAGE 12%. The proteins were blotted onto PVDF membranes and
probed with S. mansoni infected (INF), non-infected from endemic area (NE) and non-infected from non-endemic area (NI) serum pools, following an
additional incubation with anti-human Ig’s polyvalent antibody HRPO conjugated. Circle, arrows and arrowhead indicate immunogenic protein spots
which reacted exclusively with INF serum pool, while dotted circle indicates immunogenic spot which reacted exclusively with NE pooled sera. The
figure shows one representative experiment of three replicates.
doi:10.1371/journal.pntd.0002745.g003
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Table 3. Immunoreactive spots to the pooled sera of Schistosoma mansoni infected, non-infected from endemic area and non-
infected from non-endemic area volunteers identified in adult worm total and tegumental protein extracts.
SPOT number PROTEIN DESCRIPTION AW-TOT AW-TEG
INF NE NI INF NE NI
1 Fatty acid-binding protein (Sm14) 1 1 1 1 1 1
2 Superoxide dismutase [Mn] 1 1 1 1 1 1
3 14.3.3 zeta isoform 2 2 1 2 2 1
4 Glutathione S-transferase 28 kDa/Phosphoglycerate mutase 1 0 0 3 3 3
5 Glutathione S-transferase 28 kDa 3 3 2 3 3 3
6 Glutathione S-transferase 28 kDa 3 3 2 3 3 3
7 Phosphoglycerate mutase - - - 3 3 3
8 Triose phosphate isomerase 2 2 1 3 3 3
9 Phosphoglycerate mutase 1 1 1 3 3 3
10 14.3.3 epsilon isoform 2 2 1 2 2 1
11 Hemoglobinase precursor 3 3 2 2 2 1
12 Malate dehydrogenase 1 1 0 3 3 1
13 Glyceraldehyde-3-phosphate dehydrogenase 1 1 1 3 3 3
14 Major egg antigen 3 0 0 3 0 0
15 Major egg antigen 3 0 0 3 0 0
16 Glyceraldehyde-3-phosphate dehydrogenase 2 2 2 3 3 3
17 Glyceraldehyde-3-phosphate dehydrogenase 3 3 3 3 3 3
18 Glyceraldehyde-3-phosphate dehydrogenase 3 3 3 3 3 3
19 Fructose 1,6-biphosphate aldolase/Phosphoglycerate kinase 3 3 2 3 3 3
20 Fructose 1,6-biphosphate aldolase 3 3 3 3 3 3
21 Reticulocalbin/Actin-1 1 0 0 3 0 0
22 Enolase (Phosphopyruvate hydratase) 3 3 2 3 3 3
23 Aldehyde dehydrogenase 2 2 1 3 3 3
24 Transketolase 1 0 0 2 2 0
25 Glutathione S-transferase 26 kDa 2 2 1 - - -
26 Troponin I (S. japonicum) 3 3 2 - - -
27 Myosin regulatory light chain 2 2 1 - - -
28 Schistosoma mansoni, expressed protein 2 2 1 - - -
29 Glyceraldehyde-3-phosphate dehydrogenase 1 1 1 - - -
30 Glyceraldehyde-3-phosphate dehydrogenase 1 0 0 - - -
31 Troponin T 1 0 0 - - -
32 Troponin T 2 0 0 - - -
33 Fructose 1,6-biphosphate aldolase 3 2 2 3 3 3
34 ATP synthase alpha subunit mitochondrial 3 2 2 - - -
35 Heat shock protein 70 (HSP70) 2 0 1 - - -
36 Glutathione S-transferase 28 kDa/Phosphoglycerate mutase - - - 3 2 1
37 Hydroxyacylglutathione hydrolase (Glx II) - - - 3 2 1
38 Four and A half lim domains - - - 3 3 3
39 Short chain dehydrogenase/Four and A half lim domain - - - 1 1 1
40 Eukaryotic translation elongation factor - - - 0 2 0
41 Annexin/Major egg antigen - - - 3 0 0
42 Major egg antigen - - - 3 0 0
43 Aldehyde dehydrogenase - - - 3 3 3
44 Protein disulfide-isomerase ER-60 precursor - - - 3 0 0
45 Filamin - - - 3 0 0
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Table 3. Cont.
SPOT number PROTEIN DESCRIPTION AW-TOT AW-TEG
INF NE NI INF NE NI
46 No hit 3 2 1 2 2 1
AW-TOT: adult worm total protein extract, AW-TEG: adult worm tegumental protein extract. INF: 2D-WB using pooled serum of S. mansoni infected individuals, NE: 2D-
WB using pooled serum of non-infected individuals from endemic area and NI: 2D-WB using pooled serum of non-infected individuals from non-endemic area. (-): spots
not immunoreactive in the corresponding protein extracts. The numbers (0, 1, 2 and 3) indicate how many experiments each spot was detected in the triplicate of the
corresponding 2D-WB. In bold: spots immunoreactive exclusively in 2D-WB using INF serum pool. Highlighted line: spot immunoreactive exclusively to NE serum pool.
Spot numbers are related to the Figure 4.
doi:10.1371/journal.pntd.0002745.t003
Figure 4. Indication on the 2D-PAGE of the immunoreactive spots identified in 2D-WB experiments. Adult worm total (AW-TOT) and
tegumental (AW-TEG) protein extracts were separated by 2-DE using 7 cm pH 3–10 IPG strips followed by SDS-PAGE 12%, and stained by Colloidal
Coomassie Blue G-250. Protein spots immunoreactive to INF, NE and/or NI pooled sera on the 2D-WB were extracted from the corresponding 2D-
PAGE to mass spectrometry identification. The identified protein spots are numbered according to the Table 3. The figure shows one representative
experiment of three replicates.
doi:10.1371/journal.pntd.0002745.g004
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actin-activated myosin motor function in striated muscle contrac-
tion [92]. Troponin T was initially suggested to be a good
candidate for use in the diagnostic test for Taenia solium. However,
ELISA tests using pooled sera from cysticercosis-positive and
negative patients showed disappointing results [93]. Troponin
T was identified by van Balkom and co-workers [40] in a
non-tegumental fraction of S. mansoni adult worm protein extract.
Our study is in agreement with their study since we also identified
it only in total protein extract, but not in tegumental protein
extract. Another muscle protein identified in our study was actin.
Actin was also previously observed to be reactive to prepatent
infected mouse serum [94].
Reticulocalbin is a Ca2+-binding protein. It is localized in the
endoplasmic reticulum, being involved in the secretory pathway,
although its detailed role remains unknown. Overexpression of
reticulocalbin may also play a role in tumorigenesis, tumor invasion,
and drug resistance [95]. This protein has not been previously
indicated as a diagnostic test or vaccine candidate for schistosomiasis.
Immunolocalization experiments and proteomic analysis of
tegumental membrane preparations confirmed that annexin is a
protein localized mainly in the tegument of S. mansoni schistosom-
ula and adult worms [36,96]. In this study, annexin was again
identified exclusively in tegumental protein extract. Schistosoma bovis
recombinant annexin was shown to be biologically active in vitro,
with fibrinolytic and anticoagulant properties [97].
Significant attention is being given to the excretory system of
schistosomes, since accumulating evidence suggests that it plays an
important role in the host-parasite interaction. The S. mansoni
cysteine protease ER-60 is one of four members of the parasite
disulfide-isomerase protein family. It is expressed in adult worms
and larvae excretory organs, suggesting a role for ER-60 during
the host-parasite interaction [98,99]. In this study, a disulphide-
isomerase ER-60 precursor was recognized by INF serum in
tegumental protein extract.
The S. mansoni eukaryotic translation elongation factor was the
only protein identified in this study that reacted exclusively with
antibodies present in NE serum pool. In addition to its canonical
function in polypeptide chain elongation, the isoform eEF1A has
been associated to viral propagation, apoptosis in metazoans,
cytoskeleton organization and unfolded protein degradation
[100]. Moreover, elongation factor 1b/d (31 kDa) has been
shown to be immunoreactive to the sera of Echinococcus granulosus
infected patients [101]. In our study, the immunoreactive spot
corresponding to S. mansoni eukaryotic translation elongation
factor was also approximately 31 kDa.
Although we have identified only one protein that was
recognized exclusively by serum of the natural resistant individ-
uals, which represents our major candidate for a vaccine develop-
ment, all other 46 proteins identified also are candidates, once they
were recognized by antibodies present in serum of infected
Figure 5. Heat map profile of immunoreactive Schistosoma mansoni adult worm proteins to specific pooled sera. S. mansoni adult worm
total (A) and tegumental (B) protein extracts were analyzed by 2D-WB and the proteins identified by mass spectrometry were clustered according to
the reactivity pattern against to S. mansoni infected (INF), non-infected from endemic area (NE) and non-infected from non-endemic area (NI) serum
pools, in triplicate assays. Those proteins which reacted to the sera in all three assays were assigned by red color, whereas those with no detected
reactivity, by black color. Proteins which were not identified in one of the protein extracts were shown by gray color. The immunogenic proteins
which reacted exclusively to the INF serum pool are indicated by (*) and protein which reacted exclusively to the NE serum pool, by (#).
doi:10.1371/journal.pntd.0002745.g005
Schistosoma mansoni Proteome Serological Screening
PLOS Neglected Tropical Diseases | www.plosntds.org 13 March 2014 | Volume 8 | Issue 3 | e2745
individuals. The next step would be to assess the level of protection
induced by these proteins in animal models.
Expression of recombinant proteins was important to confirm
the antibody reactivity pattern, mainly for the proteins that were
weakly stained in the 2D-PAGE, as it was performed with the
major egg antigen. In vitro expressed S. mansoni major egg antigen
was strongly recognized by the INF serum pool, maintaining a
similar serum recognition pattern of the native protein which
indicates the correct spot excision. Anti-human IgG were used in
this Western blotting experiment, which means that major egg
antigen is recognized by one of the IgG subclasses. However, in
2D-WB using anti-human IgG1 and IgG3, the spots correspond-
ing to major egg antigen were no longer detectable using INF
serum pool (data not shown). Additional studies with post-
treatment sera and from individuals low stool egg counts will be
important to test its potential, as well as of other promising
candidates, as antigens for monitoring the cure and schistosomiasis
infection. This will be particularly important for those individuals
living in endemic areas for the detection of low infection rates.
The antigens identified in this study may also be used as an
immunodiagnostic test based, for example, on a qualitative
predictive model able to distinguish the clinical status of the
schistosomiasis endemic area residents.
S. mansoni hemoglobinase was also in vitro expressed in wheat
germ cell-free system to confirm the serum recognition pattern
of the 2D-WB experiment. While hemoglobinase was found to
be immunoreactive to all the pooled sera used in 2D-WB, the
recombinant protein showed to be associated with the INF
and NE pooled sera, but not with the NI. It may be due to the
use of anti-human IgG in the Western blotting instead of
anti-human Ig’s in the 2D-WB experiments, suggesting a
specific reaction of other immunoglobulin class in 2D-WB
experiments.
Serological-proteomics is a demanding methodology with a
number of arduous steps, consequently the reproducibility in
2D-WB experiments is a difficult task [102], causing missed im-
munoreactive spots in the triplicate experiments and among the
immunoblots. Furthermore, matching the immunoreactive spots
of 2D-WB to stained spots in 2D-PAGE gels used to excise the
spots to MS/MS analyses is not a trivial task. To precisely locate
immunoreactive spots in the 2D-PAGE gels, the molecular weight,
pI and the distribution pattern of spots neighboring the spot of
interest had to be taken into account. The same difficulty occurs
when matching the spots among the immunoblots. It must also be
taken into account that spots do not represent proteins but rather
protein species with post-translational modifications, partly de-
graded polypeptides, or may be splicing variants or paralogues
genes. Additionally, spots often contain several different proteins
or protein species [102].
Despite these difficulties, serological-proteomics seems to be a
good approach to characterizing the host immune response profile
to parasite antigens in a large-scale analysis, overcoming the case-
by-case and empirical science used in the past and providing
prominent antigens for the development of new schistosomiasis
diagnostics and vaccines. The manageable repertoire of S. mansoni
antigens identified in this study warrants further investigation by
profiling the antibody response of a larger panel of individual sera
using different immunoglobulin classes/subclasses. Understanding
the human immune response associated with the infection/
protection profile to these antigens represents a huge step towards
the improvement of diagnostic tools and development of vac-
cine against schistosomiasis, using not only one but multiple
antigens.
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expressed using TNT SP6 High-Yield Wheat Germ Protein Expression System and the FluoroTect GreenLys labeled proteins were analyzed in SDS-PAGE
4–20%. The gel image was obtained with a laser-based fluorescent gel scanner. The negative control using no DNA template was indicated in lane 3
and using no DNA template and no FluoroTect GreenLys, in lane 4. Lane 5 contains the Precision Plus Protein Kaleidoscope molecular weight marker
(BioRad). B) Western blotting analysis of the in vitro recombinant proteins probed with INF (2, 3, 4), NE (5, 6, 7) and NI (8, 9, 10) serum pools. The TNT
wheat germ extract using MjE flexi-vector as DNA template was loaded in lanes 2, 5 and 8, and using Hem flexi-vector in lanes 3, 6 and 9. TNT wheat
germ extract with no DNA template was loaded in lanes 4, 7 and 10. Rabbit anti-human IgG and anti-rabbit IgG HRP conjugated were used as
secondary and tertiary antibodies. The membranes were developed using ECL Plus-Western Blotting Detection System and the proteins were
visualized by chemiluminescence detection using a Fujifilm LAS-4000 Imaging System. Pre-stained Precision Plus Protein Kaleidoscope molecular
weight marker was loaded in lane 1.
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